Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
Renewal Fuels Inc. (RNWF) Discusses Ambitious Fusion Reactor Plan, Business Model and Strategy, on Stock2Me Podcast
The company aims to deliver a 100-megawatt fusion reactor in 2026, with an earlier 5-MW…
-
Navigating a Rapidly Evolving Technology Landscape: Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and the Trump Administration’s Push to Secure Domestic Supplies of Critical Minerals
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Explores GPS Alternatives in Evolving Electronic Warfare Landscape
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. The…